XTalks

APRIL 7, 2022

XTALKS WEBINAR: Cardiac Safety Solutions in Decentralized Clinical Trials (DCT). Register for this webinar to learn why cardiac safety testing is critical for clinical trial participants. This was an international, multicenter clinical trial that enrolled 200 patients over 43 sites in the US, Canada and Europe.

FDA Approval 105

FDA Approval Clinical Trials Clinical Trials Cardiology 105

Pharma Marketing Network

FEBRUARY 27, 2025

Introduction In todays digital-first world, content marketing campaigns are no longer optional for pharmaceutical brands. Imagine content marketing as the heartbeat of a pharma brands digital presence. But when done right, content marketing campaigns create lasting relationships, drive awareness, and improve patient outcomes.

Branding 52

Branding Marketing Compliance Pharma Companies 52

pharmaphorum

JUNE 17, 2022

The UK-based but US-listed biotech licensed rights to AZ’s orally-active neutrophil elastase inhibitor alvelestat for the rare disease alpha-1 antitrypsin deficiency (AATD) five years ago, and has since advanced the project into a phase 2 trial which is due to read out in the second half of this year.

Licensing 81

Licensing Licensing Cardiology Antibody 81

pharmaphorum

JUNE 1, 2021

The Danish drugmaker has acquired exclusive rights outside Japan to Heartseed’s HS-001 therapy based on heart muscle cells (cardiomyocytes) derived from human stem cells, and is due to start the phase 1/2 LAPiS trial in Japan later this year. An interim look at the results is due later this month.

Trials 138

Trials Development Licensing Licensing 138

pharmaphorum

FEBRUARY 25, 2022

. “While Jardiance may not be effective in all patients with heart failure, this approval is a significant step forward for patients and our understanding of heart failure,” says Norman Stockbridge, MD, PhD, director of the Division of Cardiology and Nephrology in the FDA’s Center for Drug Evaluation and Research.

FDA Approval 101

FDA Approval HR Cardiology Drugs 101

pharmaphorum

JUNE 22, 2021

AstraZeneca’s SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will now have to share the market with Boehringer Ingelheim and Eli Lilly’s rival therapy Jardiance. . A readout in CKD from the EMPA-Kidney is expected next year.

Sales 98

Sales Marketing FDA Approval Trials 98

pharmaphorum

OCTOBER 2, 2020

The five new NIHR National Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects. The webinar will also cover: What the NPRCs’ franchise model means for research delivery.

Clinical Trials 92

Clinical Trials Clinical Trials Clinical Research Life Science 92

pharmaphorum

JUNE 25, 2021

But Dr Craig Granowitz, chief scientific officer of cardiology drug developer Amarin, says that this is only the tip of the iceberg when it comes to the devastating impact of CVD on global populations. “In But one of the biggest issues in changing people’s expectations and improving outcomes is “apathy”, he says. Think about that.

Cardiology 100

Cardiology Drugs Development Clinical Trials 100

The Pharma Data

AUGUST 30, 2021

Results from the Phase III EMPEROR-Preserved trial were presented today at the European Society of Cardiology Congress 2021 2 and published in The New England Journal of Medicine 1. 1 Trial participants were randomly assigned to empagliflozin 10 mg (n=2,997) or placebo (n=2,991) once daily.

Trials 52

Trials Cardiology Medicine Clinical Trials 52

Velocity Clinical Research

NOVEMBER 21, 2023

Schenkenberger is especially proud of her clinical trial research work in heart health, noting most new drugs never make it to market. She’s been involved in several trials that have made a difference for patients, including Entresto, a drug that’s been “a big step forward for heart failure patients,” she says.

Medicine 59

Medicine Cardiology Clinical Research Clinical Trials 59

Delveinsight

DECEMBER 29, 2020

Myovant Sciences have decided to put their forces and efforts together to advance the Prostate cancer market as they announced their partnership deal to develop and market relugolix for prostate cancer and women’s health. . Audentes Therapeutics’ ASPIRO Trial Free to Proceed. mg and norethindrone acetate (0.5 The post A USD 4.2

Trials 52

Trials Drugs Hormones Radiology 52

pharmaphorum

OCTOBER 9, 2020

Shares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug omecamtiv mecarbil disappointed in a large phase 3 trial. It is also hoping to steal market share from rivals with biosimilars, which are comparatively cheaper versions of biologic drugs.

Trials 52

Trials Drugs Development Marketing 52

pharmaphorum

FEBRUARY 17, 2022

Bristol-Myers Squibb has new data backing up the value of mavacamten for obstructive hypertrophic cardiomyopathy (HCM), as it waits for a delayed verdict on its marketing application for the drug, acquired as part of its $13.1 billion takeover of MyoKardia in 2020.

Cardiology 59

Cardiology Trials Marketing Drugs 59

The Pharma Data

JANUARY 20, 2021

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease. The DSMC comprises independent experts who will assess the patient safety data, and, if needed, critical efficacy endpoints of the trial.

Trials 52

Trials Cardiology Containment Development 52

Velocity Clinical Research

DECEMBER 6, 2023

In addition to being one of Poland’s top recruiting sites in cardiology trials, ClinMedica also recruits patients across a broad range of therapeutic areas involving ambulatory medicine. About Velocity Clinical Research Velocity is the leading integrated site organization for clinical trials. and Europe.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

pharmaphorum

AUGUST 18, 2021

Eli Lilly and Boehringer Ingelheim have claimed FDA approval for their diabetes therapy Jardiance in heart failure with reduced ejection fraction (HFreF), setting up a market tussle with AstraZeneca’s Farxiga. Sales have rocketed ever since, climbing 30% to almost $2 billion last year, and 60% to $1.36 billion in the first half of 2021.

Cardiology 52

Cardiology Sales Marketing FDA Approval 52

XTalks

JUNE 26, 2023

According to Surmodics, SurVeil DCB is approved to be marketed and sold in the US for percutaneous transluminal angioplasty of de novo or restenotic lesions in femoral and popliteal arteries having reference vessel diameters of 4 mm to 7 mm. SurVeil has an edge over IN.PACT as it is coated with a lower dose of the drug.

FDA Approval 96

FDA Approval Drugs Sales In-Vitro 96

pharmaphorum

FEBRUARY 26, 2021

Following World War II, Ethicon’s market share in surgical sutures rose from 15% to 70% worldwide. Today, Janssen is one of the world’s leading research-based pharma companies and markets prescription medicines in the areas of gastroenterology, women’s health, mental health, neurology and HIV/AIDS, to name a few. “Dr

Sales 126

Sales Production Pharma Companies Marketing 126

The Pharma Data

OCTOBER 28, 2021

Bayer will present new renal and cardiovascular (CV) analyses from the comprehensive finerenone (Kerendia®) clinical trial program, including the Phase III FIGARO-DKD and FIDELIO-DKD studies, and the prespecified pooled analysis FIDELITY at the American Society of Nephrology (ASN)’s Kidney Week 2021 from 4-7 November.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Branding 52

pharmaphorum

JULY 7, 2021

The results of the much-anticipated EMPEROR-Preserved trial found that SGLT2 inhibitor Jardiance (empagliflozin) reduced the risk of cardiovascular death or hospitalisation for heart failure in adults with HFpEF, which accounts for around half of all heart failure cases.

Sales 52

Sales Cardiology FDA Approval Trials 52

pharmaphorum

JANUARY 5, 2021

If they had also predicted that the second person to receive the vaccine out of trial would be a gentleman named William Shakespeare, they would certainly have been dismissed as a fantasist. “The real impact on submissions and approvals will be in 2021 and beyond, when the pandemic’s true impact on clinical trials becomes apparent”.

Sales 105

Sales Marketing Production Vaccination 105

pharmaphorum

MAY 18, 2021

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal. Data were announced at the virtual American College of Cardiology annual conference and published simultaneously in The Lancet.

Drugs 52

Drugs Cardiology Trials Clinical Trials 52

pharmaphorum

JANUARY 12, 2021

The US regulator is looking at data from the EMPEROR-Reduced trial of Jardiance (empagliflozin), which found that the drug achieved a 25% reduction in the combined primary endpoint of cardiovascular death or hospitalisation compared to placebo.

Sales 76

Sales FDA Approval Trials Marketing 76

Delveinsight

AUGUST 3, 2021

DelveInsight’s analysis in the report titled, DelveInsight’s Chronic Pain associated with Painful Diabetic Neuropathy – Epidemiology Forecast – 2030 Market Insights, Competitive Landscape and, Market Forecast – 2026 , the market size of the Senza Omnia system is estimated to increase to around USD 3,500 million by 2026.

FDA Approval 98

FDA Approval Marketing Cardiology Production 98

ACRP blog

JANUARY 24, 2023

Bringing our visions for clinical research to life in local communities with little knowledge of the role and benefits of clinical trials initially proved more difficult than we expected,” says Kristen Gurnea, MPH, CCRC, ACRP-PM, Manager of Clinical Research, Renown Health. “We

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

The Pharma Data

JUNE 28, 2021

The approval is based on the results of the pivotal Phase III VICTORIA trial, published in The New England Journal of Medicine (NEJM) in March 2020. Bayer is proud of the approval of vericiguat in Japan and the contribution it has shown in clinical trials.”. Verquvo (vericiguat) 2.5 Verquvo (vericiguat) was approved by the U.S.

Cardiology 52

Cardiology Production Development Medicine 52

Velocity Clinical Research

MARCH 7, 2024

It’s easy to hear the enthusiasm for clinical trials when William Cromwell, MD, FAHA, FNLA , Principal Investigator and a leader of the Velocity Cardiometabolic CARE Council , discusses their importance to patients yesterday, today, and tomorrow.

Doctors 52

Doctors Doctor Clinical Research Clinical Trials 52

Delveinsight

AUGUST 4, 2020

MorphoSys in-licensed Monjuvi, which is a humanized Fc-engineered monoclonal antibody against CD19 – the same protein which CAR-T cell therapies target and is in abundance in cancerous B cells, from Xencor in 2010 and is under evaluation in B-cell malignancies in several ongoing combination trials.

Cardiology 55

Cardiology Antibody FDA Approval Trials 55

Delveinsight

JULY 22, 2021

This early-stage trial is set to enroll ten patients across the US and Canada, with its primary aim to evaluate the safety and tolerability of DA01 cell transplantation at one year post-transplant. BlueRock Therapeutics secures FDA fast track for Parkinson’s disease cell therapy.

Cardiology 98

Cardiology Development Engineer Clinical Trials 98

pharmaphorum

AUGUST 13, 2020

The cholesterol-lowering drug has been classed as a breakthrough therapy for homozygous familial hypercholesterolaemia (HoFH) by the FDA, which is due to deliver a decision on the marketing application by 11 February after a truncated six-month review.

Drugs 52

Drugs Antibody Sales Cardiology 52

XTalks

AUGUST 22, 2022

The Toronto-based company has recently announced positive results from an independent clinical trial which showed that their fluorescence imaging device MolecuLight i :X improved 12-week wound healing of diabetic foot ulcers by 204 percent. Orthopaedics have X-ray, cardiology has echocardiography, cancer has ultrasound, PET, CT and MRI.

Bacteria 111

Bacteria Containment Sales Cardiology 111

pharmaphorum

OCTOBER 2, 2020

The five new NHS Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects. The webinar will also cover: What the NPRCs’ franchise model means for research delivery.

Clinical Trials 52

Clinical Trials Clinical Trials Clinical Research Life Science 52

pharmaphorum

FEBRUARY 10, 2022

The decision gives Bayer a shot at narrowing the gap with its main rivals in the category – Bristol-Myers Squibb and Johnson & Johnson – which are thought to be out in front the in race to bring an oral FXIa inhibitor to market with their milvexian candidate.

Drugs 98

Drugs Sales Antibody Regulation 98

The Pharma Data

FEBRUARY 21, 2022

Our leadership in cardiology, radiology and women’s health is recognized worldwide, and we are expanding our presence in oncology, working tirelessly to bring forward new approaches that can change the treatment paradigm for patients,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division.

Radiology 52

Radiology Cardiology Development Production 52

XTalks

JUNE 11, 2024

The FDA’s approval is based on positive results from the AGENT IDE trial , a multicenter, prospective, randomized controlled study, which demonstrated the statistical superiority of Agent DCB over uncoated balloon angioplasty in preventing target lesion failure (TLF) at 12 months.

Drugs 52

Drugs Drug Delivery Cardiology Marketing 52

The Pharma Data

JULY 12, 2021

Bakris, MD, Department of Medicine, American Heart Association Comprehensive Hypertension Center, University of Chicago Medicine, USA and principal investigator of the FIDELIO-DKD trial. FDA has approved finerenone for marketing authorization in the U.S. Based on the positive data from FIDELIO-DKD, the U.S.

FDA Approval 52

FDA Approval Cardiology Medicine Trials 52

The Pharma Data

OCTOBER 14, 2020

“The global heart failure market represents a tremendous opportunity for Sequana Medical and we look forward to providing an update on the interim results from our RED DESERT study later this year.”. market for the alfa pump resulting from NASH-related cirrhosis is forecast to exceed €3 billion annually within the next 10-20 years.

Cardiology 40

Cardiology Clinical Trials Clinical Trials Medicine 40